|
Hereditary Angioedema (HAE) Research Highlights: 2022 AAAAI Annual Meeting
This accredited CME activity, led by Paula Busse, MD, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, provides a summary of the latest information about hereditary angioedema (HAE) that was presented at the American Academy of Allergy, Asthma, & Immunology 2022 (2022 AAAAI) Annual Meeting. This program was developed to provide a concise means to share the clinically relevant information presented at the meeting with health care professionals who my care for ... |
|
Diagnosis and Evidence-Based Management of T-Cell Lymphoma
STATEMENT OF NEED
T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinic... |
|
|
Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis
Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now!
STATEMENT OF NEED
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bon... |
|
|
Key Considerations in Managing Atopic Dermatitis in Black Patients
Statement of Need
Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong & Tay, 2017). Population studies within the United States have shown that AD disproportionately... |
|
|
Podcast: Key Considerations in Managing Atopic Dermatitis in Black Patients
Statement of Need
Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong & Tay, 2017). Population studies within the United States have shown that AD disproportionately... |
|
|
New Perspectives in the Management of Marginal Zone Lymphoma
STATEMENT OF NEED
Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from memory B lymphocytes located in the marginal zone of secondary lymphoid follicles present in the spleen; and nodal MZL, which originates in... |
|
|
New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease
STATEMENT OF NEED
Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; howe... |
|
|
Podcast: New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease
STATEMENT OF NEED
Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; howe... |
|
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
CIPN is a complication of cancer treatment that may lead to permanent nerve damage in severe cases. This online activity reviews causative agents, signs and symptoms, and supportive care interventions.
1.0 NCPD | ILNA
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductions or discontinuation in severe cases. In one study of 123 patients receiving taxane therapy for bre... |
|
|
Diagnosis & Comorbidities in Cushing’s Disease: Incorporating the New Consensus Summary Into Your Practice
This 30 minute CME program highlights the latest expert consensus on best practices for diagnosing Cushing’s disease and managing the comorbidities commonly observed in persons with this rare disorder.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Optimal patient outcomes require an accurate diagnosis, proper selection of individualized treatment, and good management of the disease and its associated comorbidities.
The program feature... |
|
|
Updates in Medical Management of Cushing’s Syndrome: Incorporating the New Consensus Summary into Your Practice
This 30 minute CME program highlights the latest expert consensus on best practices for the treatment of persons with Cushing’s disease.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Optimal patient outcomes require an accurate diagnosis, proper selection of individualized treatment, and good management of the disease and its associated comorbidities.
The program features two experts, Maria Fleseriu, MD, Professor of Medicine and Neur... |
|
|
Advances in Gene Therapy for Lysosomal Diseases
This CME/CE activity highlights the current trends in gene therapy for lysosomal storage diseases as well as some of the safety concerns with such therapy.
This activity provides continuing education credit for Physicians, Physician Assistants, Nurse Practitioners, Nurses, Genetic Counselors as well as a statement of participation for other participants. |
|
|
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer
This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.
Statement of Need
An ... |
|
|
Novel Breast Cancer Therapies: Antibody-Drug Conjugates
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s... |
|
|
Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is
estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit... |
|
|
Novel Breast Cancer Therapies: CDK4/6 Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T... |
|
|
Novel Breast Cancer Therapies: HER2 Tyrosine Kinase Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-positive breast cancer. These agents have advantages over monoclonal antibody HER2 inhibitors because the... |
|
|
Novel Breast Cancer Therapies: Monoclonal Antibodies
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are human epidermal growth factor receptor 2 (HER2)"positive and may therefore benefit from HER2 inhibition (ACS, 2019). Monoclonal antibodies target HER2 function by preventing the formation or blocking the signaling of the oncogene HER2. The resulting loss of signaling downregulates oncogenic signaling in the cancer cell, resulting in improved clinical outcomes for pati... |
|
|
Novel Breast Cancer Therapies: PARP Inhibitors
STATEMENT OF NEED
Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly"(ADP-ribose) polymerase (PARP) is highly ef... |
|
|
Novel Breast Cancer Therapies: PI3K Inhibitors
STATEMENT OF NEED
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers... |
|
|
Growth Hormone Deficiency Research Highlights
This 15-minute CME program highlights the latest clinical research about Growth Hormone Deficiency (GHD).
GHD is a rare endocrine disorder characterized by insufficient levels of growth hormone being secreted from the anterior pituitary gland. A hallmark of prolonged GHD is growth retardation or deceleration, as well as short stature. Additionally, growth hormone deficiency is associated with metabolic abnormalities, impaired cardiovascular function, fatigue, delayed or incomplete puberty, ... |
|
|
PAH Research Highlights from CHEST
PAH is a rare, progressive disorder characterized by high blood pressure in the pulmonary arteries. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. The progressive nature of this disease means that an individual may experience only mild symptoms at first, but will eventually require treatment and medical care to maintain a reasonable quality of life. There are numerous treatment options and options in development for persons ... |
|
|
Cushing’s Disease / Cushing’s Syndrome Research Highlights
This 30-minute CME program highlights the latest clinical research about Cushing’s disease and Cushing’s syndrome.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor that leads to excessive levels of cortisol. Cushing’s syndrome is also characterized by excessive levels of cortisol but can be due to a variety of reasons.
This CME program, hosted by Richard Auchus, MD, PhD Professor at the University of Michigan, provides an overview of ... |
|
|
Evolving Treatment Concepts and New Data in Advanced Prostate Cancer
STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health care providers to be familiar with the most recent evidence on therapy selection, biomarker testing... |
|
|
Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma
STATEMENT OF NEED
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their... |
|
|
Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Modul... |
|
|
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Cancers
STATEMENT OF NEED
Esophagogastric cancers include tumors of the esophagus, esophageal junction, and stomach. Esophageal cancers are the twentieth most commonly diagnosed cancer in the United States, but the eleventh leading cause of cancer death, with an estimated 21,560 cases diagnosed annually and 16,120 deaths estimated in 2023 (NCCN, 2023; Siegel et al, 2023). Given the poor prognosis of esophagogastric cancers and the complexity of personalized care planning, interdisciplinary teamwork... |
|
|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Monoclonal Antibodies For COVID-19: An Update on Best Practices
Target Audience
The educational design of this activity addresses the needs of infectious disease clinicians, internal medicine clinicians, and primary care providers, including physicians, nurse practitioners, and physician assistants, involved in the care of patients with mild or moderate coronavirus disease 2019 (COVID-19) who are at risk for clinical progression (eg, older patients, immunocompromised patients, patients with certain comorbidities).
Statement of Need/Program Overview
As... |
|
|
Addressing Disparities and Systemic Racism in HIV Prevention
This free interactive CME/CNE-Certified webinar is designed for members of the care team to help you identify disparities and systemic racism in HIV prevention and care, and to identify and implement strategies with your team to combat them. |
|
|
Virologic Failure in HIV: An Updated Clinician’s Guide to Assessment and Management
Target Audience
The educational design of this activity addresses the needs of infectious disease and HIV-specialist physicians and other clinicians involved in the care of patients with HIV infection.
Statement of Need/Program Overview
Though the prevalence of virologic failure (VF) in patients with HIV has decreased as newer antiretroviral (ART) regimens with higher genetic barriers to resistance and reduced toxicity have been approved, VF can still occur. VF may be due to patient, vi... |
|
|
Two Pediatric Bone Disorders in the Era of Disease Specific Therapies – When to Refer Patients and How to Treat XLH and HPP
Target Audience
This activity is designed to meet the educational needs of pediatricians in endocrinology, primary care, rheumatology, orthopedics, neurology, radiology, nephrology, neonatology, and other speciaties. Healthcare providers including geneticists and genetic counselors are included.
Program Overview
X-linked hypophosphatemia (XLH) and hypophosphotasia (HPP) are genetic metabolic bone diseases with recent treatment advances. This program will discuss when to refer and how ... |
|
|
Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago Race, Ethnicity, and Breast Cancer: Screening and Diagnosis
This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses screening and mammography rates am... |
|
|
Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago Race, Ethnicity, and Breast Cancer: Treatment
This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses the oncology, surgical, and radiat... |
|
|
Keeping Up with Advances in MS: Cases in Diagnoses and Treatment, A Case-Based Roadmap for Improved Patient Outcomes in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, progressive, and disabling inflammatory neurologic condition that causes more disability than any other nontraumatic neurologic condition. Early diagnosis, treatment, and monitoring of disease progression is fundamental to optimizing management of patients with MS. Join Edward Fox, MD, PhD, and Matthew Schindler, MD, PhD, in an interactive case-based roadmap for improved outcomes in patients with MS. In addition to addressing diagnostic challenges, Drs. Fo... |
|
|
Opioid Issues in Youth Pain Management for Orthopedic Injuries
This course familiarizes physicians with current guidelines for opioid prescribing, focusing on safe prescribing practices when dealing with adolescents. Non-opioid treatments for orthopedic injuries are also reviewed.
Outcome Objectives:
As a result of completing this activity, the participant will be better able to:
- Manage adolescent non-cancer pain using non-opioid therapies.
- Cite at least two key safe opioid prescribing practices from state or CDC guidelines.
- Review trend... |
|
|
Update CME: Internal Medicine and Primary Care Livestream Rebroadcast June 2023
This livestreamed conference (7.30 a.m. June 22 - 1.00 p.m. June 25) is organized by the American Medical Forum. Eminent speakers from The University of Chicago, Rush University, and Northwestern University will present the most advanced clinical guidelines. The course also offers live Q&A, and each speaker will take the time to answer your questions submitted via online poll. At the conclusion, participants will be able to incorporate the most up-to-date treatment strategies to general ch... |
|
|
A New Era: Targeting Iron Deficiency to Improve Heart Failure Outcomes
Dive into the current and emerging diagnostic approaches to support iron deficiency (ID) as a treatment target for heart failure (HF) with a panel of experts. This activity features case discussions that demonstrate best practices in the clinical assessment and diagnosis of ID, as well as its management in patients with HF to improve awareness around “medical misses” for optimal patient outcomes. This learning opportunity will also focus on reviewing the clinical impact of intravenous iron... |
|
|
Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice - Optimizing PrEP Access Through Advocacy
This activity will focus on medication therapy management protocols and their impact on prescription drug coverage policies. It also will look at PrEP access through a health equity lens and will include a review of the drug utilization review process, insurance models, and health impact analysis"considering the impact of each on patients and care. |
|
|
Cleveland Clinic Diabetes Therapeutics, Technology and Surgery (Online Streaming On Demand)
For over twenty five years, Cleveland Clinic has been at the forefront of diabetes treatment, research and education. Its world class faculty has designed Diabetes Therapeutics, Technology and Surgery to provide up-to-date reviews of management strategies and research on the complications of this disease. It includes a detailed analysis of therapeutic options applicable to type 1 and type 2 diabetes, as well as their complications. Worth 6.25 AMA PRA Category I Credits™, this enduring mat... |
|
|
Community Conversations: Real-World Strategies for Overcoming Disparities in Immunotherapy Cancer Care
These powerful and captivating stories follow real-world patients on their immunotherapy journeys. Multidisciplinary cancer care clinicians also provide insightful perspectives on these stories. Experts review the latest data and guidance to frame ongoing disparities with immunotherapy access and share strategies to overcome barriers and broaden therapeutic opportunities for underserved patient populations. Don’t miss this powerful documentary-style education that will help you close the o... |
|
|
Treating Obesity 2023: The Blackburn Course in Obesity Medicine - LIVE STREAMING
Education to Optimize Your Care of Adult, Adolescent, and Pediatric Patients with Obesity
This highly-rated Harvard Medical School CME course delivers practical strategies to optimize the management of obesity and its many complications, and provides the most up-to-date approaches to obesity prevention and treatment.
Highlights of the 2023 program include:
• Comprehensive evaluation of the patient with obesity
• Medical management of the patient with obesity
• Emerging precision med... |
|
|
Lifestyle Medicine: Tools for Promoting Healthy Change - LIVE STREAMING
State-of-the-Art Approaches to Help Patients Initiate and Sustain Health-Promoting Behaviors
Overview
This immersive two-day Harvard Medical School CME course"among Harvard’s highest-rated CME courses"offers state-of-the-art strategies to guide patients to healthier lives. Education includes evidence-based strategies, tools and techniques to effect healthier changes in patients (and ourselves), including nutrition, exercise, sleep, weight loss, and stress management. This cours... |
|
|
NeuroRehabilitation 2023 - LIVE STREAMING
Comprehensive Neurorehabilitation Update
Cutting-edge strategies, updates, and best practices for state-of-the-art rehabilitation
In this Harvard Medical School CME course, many of the country’s most experienced and committed neurorehabilitation experts will present cutting-edge clinical interventions, the latest findings, practical education, and hands-on methods to further your expertise in guiding your patients to their maximum level of function.
Clinicians who provide care for pa... |
|
|
Internal Medicine Comprehensive Review and Update 2023 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 63rd Annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine
• Infectious... |
|
|
Gastroenterology 2023 - LIVE STREAMING
The Comprehensive 2023 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2023 program include:
• Updated g... |
|
|
Lessons Learned and New Opportunities: Strategies for Meaningful and Sustainable Improvements to Reduce Health Disparities in Prostate Cancer
This interactive tool is interspersed with videos of leading experts in prostate cancer disparities research. The materials and resources provided in this activity help learners become better able to identify systemic, behavioral, and sociocultural variables that continue to contribute to prostate cancer inequities. The experts in this activity provide insights and resources for learners to help address these disparities not only on patient level, but also within their own institution.
Are ... |
|
|
Initial Therapy Matters for Clostridioides difficile " Get it Right the First Time
Never miss a diagnosis of Clostridioides difficile (C. difficile) infection again! This engaging activity features a dive into the diagnosis and treatment of community-acquired C. difficile infection with a multidisciplinary expert panel in a roundtable discussion. In this one-of-a-kind educational experience, a captivating moderator leads a team of 3 physicians from internal medicine, infectious disease, and gastroenterology to provide clinical commentary on the latest guidelines and best pra... |
|